Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ANNX
Strong SellSinkerAnnexon, Inc. · Healthcare · United States · $942M · Avg Vol: $11M/d
COMPANY DESCRIPTION
Annexon, Inc. is a clinical-stage biopharmaceutical company focused on developing novel C1q and classical complement pathway inhibitors to treat a range of autoimmune, neurodegenerative, and ophthalmic diseases. The company's proprietary antibody platform targets a specific component of the immune system, aiming to halt disease progression by preventing complement-mediated damage. Its competitive edge lies in its pioneering scientific approach to complement biology and the potential breadth of its therapeutic applications.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | — | — | — | 38.9M | — |
| EPS | -3.40 | -0.76 | -0.85 | -1.01 | -1.34 | — | -1.13 | -1.05 | -1.08 | — |
| Shares | 38.6M | 163.8M | 163.8M | 109.4M | 149.4M | +287.3% | 189.6M | — | — | — |
| Debt | 34.6M | 32.9M | 31.4M | 29.0M | 26.2M | -6.7% | 24.7M | — | — | — |
| Equity | 231.9M | 231.2M | 250.6M | 293.1M | 211.6M | -2.3% | — | — | — | — |
| Op CF | -106.1M | -116.3M | -121.1M | -118.0M | -186.4M | — | -193.0M | — | — | — |
| Inv CF | -88.2M | 58.4M | 70.7M | -218.8M | 190.1M | — | — | — | — | — |
| Fin CF | 1.8M | 122.9M | 135.5M | 161.2M | 108.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ANNX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ANNX | Annexon, Inc.(you) | $942M | 6 | Strong Sell |
| ATTO | Attovia Therapeutics, Inc. | $891M | 7 | Strong Sell |
| OLMA | Olema Pharmaceuticals, Inc. | $899M | 6 | Strong Sell |
| OBX | Obsidian Therapeutics, Inc. | $1.0B | 4 | Strong Sell |
| WVE | Wave Life Sciences, Inc. | $993M | 3 | Strong Sell |
| SANA | Sana Biotechnology, Inc. | $1.2B | 7 | Strong Sell |
| ODTX | Odyssey Therapeutics, Inc. | $1.2B | 4 | Strong Sell |
| CRVS | Corvus Pharmaceuticals, Inc. | $1.2B | 8 | Strong Sell |
| BBOT | BridgeBio Oncology Therapeutics, Inc. | $701M | 8 | Strong Sell |
| 950260.KQ | Ingenia Therapeutics Inc. | $649M | 7 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%